Evidence map›Paper›PMID 25461534›Full record

ArticleVirology2014

HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.

Michael A Thomas, Iskra Tuero, Thorsten Demberg, Diego A Vargas-Inchaustegui, Thomas Musich, Peng Xiao, David Venzon, Celia LaBranche, David C Montefiori, Janet DiPasquale and 6 more

Open access · greenAbstract read
In one paragraph

Article in Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. E4orf1 SuppressesVaccines · 2022
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Prospecting for an HIV vaccine.Tropical diseases, travel medicine and vaccines · 2017
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Michael A ThomasSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Iskra TueroSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Thorsten DembergSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Diego A Vargas-InchausteguiSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Thomas MusichSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Peng XiaoSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
David VenzonBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Celia LaBrancheDuke University Medical Center, Durham, NC 27710, United States.
David C MontefioriDuke University Medical Center, Durham, NC 27710, United States.
Janet DiPasqualeSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Steven G ReedInfectious Diseases Research Institute, Seattle, WA 98102, United States.
Anthony DeVicoInstitute of Human Virology, University of Maryland, Baltimore, MD, United States.
Timothy FoutsProfectus BioSciences, Inc., Baltimore, MD 21224, United States.
George K LewisInstitute of Human Virology, University of Maryland, Baltimore, MD, United States.
Robert C GalloInstitute of Human Virology, University of Maryland, Baltimore, MD, United States.
Marjorie Robert-GuroffSection on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: guroffm@mail.nih.gov.
National Institutes of Health · USUniversity of Maryland, Baltimore · USDuke Medical Center · USInfectious Disease Research Institute · USProfectus Biosciences (United States) · US

Funding

Development of a Vaccine for HIVAIDS: Humoral ImmunityZIABC011058 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$23.3M
Development of a Vaccine for HIVAIDS: Cellular ImmunityZIABC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$12.8M
Intramural NIH HHS ZIA BC011058
6 · The paper itself

Abstract

To target the HIV CD4i envelope epitope, we primed rhesus macaques with replicating Ad-rhFLSC (HIV-1BaLgp120 linked to macaque CD4 D1 and D2), with or without Ad-SIVgag and Ad-SIVnef. Macaques were boosted with rhFLSC protein. Memory T-cells in PBMC, bronchoalveolar lavage and rectal tissue, antibodies with neutralizing and ADCC activity, and Env-specific secretory IgA in rectal secretions were elicited. Although protective neutralizing antibody levels were induced, SHIVSF162P4 acquisition following rectal challenge was not prevented. Rapid declines in serum ADCC activity, Env-specific memory B cells in PBMC and bone marrow, and systemic and mucosal memory T cells were observed immediately post-challenge together with delayed anamnestic responses. Innate immune signaling resulting from persisting Ad replication and the TLR-4 booster adjuvant may have been in conflict and reoriented adaptive immunity. A different adjuvant paired with replicating Ad, or a longer post-prime interval allowing vector clearance before boosting might foster persistent T- and B-cell memory.

Indexed as

AIDS VaccinesAnimalsAntibody-Dependent Cell CytotoxicityB-LymphocytesCD4 AntigensEpitopesFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsMacaca mulattaMaleRectumT-LymphocytesViral LoadAIDS VaccinesCD4 AntigensEpitopesgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120Antibody-dependent cellular cytotoxicityHIV CD4i epitopeHIV vaccineMemory B and T cellsNeutralizing antibodyReplication-competent AdRhesus macaque modelSystemic and mucosal adaptive immunity

Identifiers

PMID25461534
PMCPMC4312258
OpenAlexW2063420710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.